Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma

被引:28
作者
Erkinheimo, TL
Sivula, A
Lassus, H
Heinonen, M
Furneaux, H
Haglund, C
Butzow, R
Ristimäki, A
机构
[1] Univ Helsinki, Dept Obstet & Gynecol, Helsinki, Finland
[2] Univ Helsinki, Dept Pathol, Helsinki, Finland
[3] Univ Helsinki, Dept Surg, Helsinki, Finland
[4] Univ Helsinki, Biomedicum Helsinki, Mol & Canc Biol Res Program, Helsinki, Finland
[5] Univ Helsinki, Cent Hosp, Helsinki, Finland
[6] Univ Connecticut, Ctr Hlth, Dept Biochem, Ctr Vasc Biol, Storrs, CT 06269 USA
基金
芬兰科学院;
关键词
HuR; COX-2; inhibin-alpha; ovarian cancer; mucinous;
D O I
10.1016/j.ygyno.2005.04.047
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cyclooxygenase-2 (COX-2) expression has been found to associate with poor prognosis in several types of carcinomas. HuR is an mRNA stability protein and it regulates the expression of COX-2. Objectives and methods. We analyzed the expression of COX-2 and HuR in 64 mucinous ovarian carcinoma specimens by immunohistochemistry. Results. In mucinous tumors, high COX-2 protein expression was found in epithelial cancer cells in 39% (22/56) and in stromal cells in 24% (13/55) of the specimens. The expression of COX-2 in cancer cells correlated with high grade (P = 0.0285), but stromal COX-2 expression had no correlation with any clinical parameter tested. Cytoplasmic HuR protein expression was observed in cancer cells in 47% (27/57) and in stromal cells in 7% (4/56) of the mucinous tumors, and it correlated with COX-2 expression in the cancer cells (P = 0.0162) but not in the stroma. Conclusion. Our results support the hypothesis that cytoplasmic HuR is connected to COX-2 expression in ovarian carcinoma, but that its role is restricted to the transformed epithelial cancer cells. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:14 / 19
页数:6
相关论文
共 39 条
[11]   Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients [J].
Ferrandina, G ;
Lauriola, L ;
Zannoni, GF ;
Fagotti, A ;
Fanfani, F ;
Legge, F ;
Maggiano, N ;
Gessi, M ;
Mancuso, S ;
Ranelletti, FO ;
Scambia, G .
ANNALS OF ONCOLOGY, 2002, 13 (08) :1205-1211
[12]   Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications [J].
Ferrandina, G ;
Lauriola, L ;
Zannoni, GF ;
Distefano, MG ;
Legge, F ;
Salutari, V ;
Gessi, M ;
Maggiano, N ;
Scambia, G ;
Ranelletti, FO .
BRITISH JOURNAL OF CANCER, 2002, 87 (10) :1145-1152
[13]   Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer [J].
Ferrandina, G ;
Ranelletti, FO ;
Lauriola, L ;
Fanfani, F ;
Legge, F ;
Mottolese, M ;
Nicotra, MR ;
Natali, PG ;
Zakut, VH ;
Scambia, G .
GYNECOLOGIC ONCOLOGY, 2002, 85 (02) :305-310
[14]   Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma [J].
Gallo, O ;
Schiavone, N ;
Papucci, L ;
Sardi, I ;
Magnelli, L ;
Franchi, A ;
Masini, E ;
Capaccioli, S .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (02) :723-732
[15]  
Heintz A P, 2001, J Epidemiol Biostat, V6, P107
[16]   Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice [J].
Hull, MA ;
Booth, JK ;
Tisbury, A ;
Scott, N ;
Bonifer, C ;
Markham, AF ;
Coletta, PL .
BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) :1399-1405
[17]  
KLEMI PJ, 1995, CANCER, V76, P1201, DOI 10.1002/1097-0142(19951001)76:7<1201::AID-CNCR2820760716>3.0.CO
[18]  
2-L
[19]   Tissue microarrays for high-throughput molecular profiling of tumor specimens [J].
Kononen, J ;
Bubendorf, L ;
Kallioniemi, A ;
Bärlund, M ;
Schraml, P ;
Leighton, S ;
Torhorst, J ;
Mihatsch, MJ ;
Sauter, G ;
Kallioniemi, OP .
NATURE MEDICINE, 1998, 4 (07) :844-847
[20]   Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies [J].
Landen, CN ;
Mathur, SP ;
Richardson, MS ;
Creasman, WT .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 188 (05) :1174-1176